Are new drugs included on the PDL?
If a therapeutic class has been reviewed by the P & T Committee and the Secretary of DHHR has approved the recommended drugs in that category, new chemical entities will be considered non-preferred until the drug is reviewed at a subsequent meeting. If a new chemical entity is considered unique and has been classified as a priority drug by the FDA, the Bureau may indicate that this drug is preferred until the class is once again reviewed. Recommendations regarding the PDL status of new medications will be made by the State’s current vendor at the time of the next review of the therapeutic class to which that medication belongs. The schedule for these class reviews may be altered if new medications are determined to have a significant clinical and/or financial impact. This process does not always apply to line item extensions, such as new strengths or dosage forms of previously available medications.
